• No results found

PHENOTYPE AND IMMUNOMODULATORY PROPERTIES OF PαS MSCs

3.1   Chapter Rationale and Aims

3.3.1   Chapter Summary

PαS   MSCs   were   successfully   isolated   and   cultured   according   to   previously   published   protocols  (Houlihan  et  al.,  2012).  These  cells  had  characteristic  spindle-­‐shaped  morphology,   were  able  to  form  CFU-­‐F  and  undergo  tri-­‐lineage  differentiation  into  bone,  fat  and  cartilage.   PαS   MSCs   were   also   able   to   be   expanded   in   standard   culture   conditions   and   expressed   characteristic   MSC   markers,   thereby   meeting   the   ISCT   criteria   for   MSCs   (Dominici   et   al.,   2006).   The   immunosuppressive   phenotype   of   PαS   MSCs   have   also   been   described   for   the   first  time,  with  different  wild  type  mouse  strains  utilising  distinct  mechanisms  to  suppress  T   cell   proliferation.   Balb/c-­‐derived   PαS   MSCs   secreted   NO   to   inhibit   CD4   lymphocytes   that   were  stimulated  with  anti-­‐CD3e  antibody  and  CD19  B  cells.  C57BL/6-­‐derived  PαS  MSCs  failed   to   suppress   in   the   same   assay,   and   required   the   development   of   a   more   complex   in   vitro   system  involving  the  use  of  TCR  transgenic  OT-­‐1  mice.  Preliminary  results  show  reduction  in   CD8   T   cell   numbers   after   co-­‐culture   with   C57BL/6-­‐PαS   MSCs   in   the   splenocyte   reaction,   although  more  work  is  required  to  elucidate  the  mechanism  behind  this.  

 

  3.3.2  Phenotype  of  PαS  MSCs  

Protocols   for   the   prospective   isolation   of   murine   MSCs   represent   a   major   advance   in   the   field.  PαS  MSC  yields  achieved  from  C57BL/6  and  Balb/c  mice  were  similar  in  number  to  the   ones   reported   by   Morikawa   et   al.   (2009).   Approximately   5000   to   8000   PαS   MSCs   were   isolated   per   mouse,   and   the   flow   cytometry   plots   looked   similar   to   the   original   study.   All  

cells   were   fibroblastic   in   morphology,   and   cell   surface   staining   revealed   <1%   positivity   for   haematopoietic   or   leukocytic   markers   in   PαS   cultures   after   one   passage.   This   compares   favourably   with   older   protocols   in   which   leukocytic   cells   persisted   in   culture   for   several   weeks,   even   after   serial   passaging   (Meirelles   Lda   and   Nardi,   2003,   Phinney   et   al.,   1999).   Population  doubling  times  for  PαS  cells  at  early  passage  was  approximately  55  hours,  which   is   similar   to   the   50.6   hours   reported   by   Morikawa   and   colleagues.   Interestingly,   we   only   observed  a  CFU-­‐F  forming  efficiency  of  1  in  every  66  PαS  MSCs,  which  is  lower  than  the  1  in   50  reported  by  Morikawa  et  al.  (2009).  As  CFU-­‐F  was  performed  on  freshly-­‐sorted  PαS  MSCs,   cell  death  due  to  the  sorting  procedure  may  have  negatively  affected  the  CFU-­‐F  efficiency.   Pinho   et   al.   (2013)   report   similar   CFU-­‐F   forming   efficiency   in   PDGFRα+CD51+   MSCs,   and  

suggest  that  the  “harsh”  sorting  procedure  adversely  affects  their  cell  viability.  I  did  observe   some  dead,  floating  cells  in  PαS  MSC  cultures  24  hours  after  cell  sorting,  which  gives  further   evidence   for   this   theory.   As   such,   PDGFRα   and   Sca-­‐1   enriches   for   cells   with   MSC-­‐like   phenotype  from  mouse  BM,  but  not  every  PαS  MSC  can  perform  all  the  functions  expected   of   MSCs.   However,   the   CFU-­‐F   efficiency   of   PαS   MSCs   is   significantly   higher   than   those   reported  in  plastic-­‐adherent  studies,  which  range  from  1  in  every  9000  BM  cells  (Meirelles   Lda  and  Nardi,  2003)  to  1  in  3.3x106  BM  cells  (Phinney  et  al.,  1999).    

 

The  tri-­‐lineage  differentiation  of  PαS  MSCs  was  demonstrated  using  well-­‐established  in  vitro   techniques.   PαS   MSCs   readily   underwent   osteogenic   and   chondrogenic   differentiation,   although   adipogenic   differentiation   was   less   impressive.   Clonal   PαS   MSC   differentiation   studies   by   Morikawa   et   al.   revealed   all   clones   (6/6)   could   differentiate   towards   bone   and  

cartilage,   but   less   than   half   (2/6)   could   differentiate   towards   fat   (Morikawa   et   al.,   2009).   Poor  adipogenic  differentiation  (relative  to  osteogenic  differentiation)  was  also  observed  in   previous  studies  of  mouse  (Cunha  et  al.,  2013),  sheep  (Heidari  et  al.,  2013),  and  rat  (Peng  et   al.,  2008)  MSC  populations.    The  reasons  behind  this  disparity  are  unclear  and  could  be  due   to  heterogeneity  in  the  PDGFRα+Sca-­‐1+  population  or  the  fact  that  BM  MSCs  are  naturally   primed  towards  bone  and  cartilage  (skeletal  tissue)  over  fat  (connective  tissue).  Additionally,   culture  on  a  stiff  surface  has  also  been  shown  to  enhance  osteogenic  differentiation  in  MSC   populations  (Engler  et  al.,  2006).    

 

  3.2.3  Immunosuppressive  phenotype  of  PαS  MSCs  

In   vitro   T   cell   suppression   assays   demonstrated   that   Balb/c-­‐derived   PαS   MSCs   suppressed  

CD4   T   cell   proliferation   in   a   dose-­‐dependent   manner.   Blocking   studies   revealed   that   local   release  of  NO  by  PαS  MSCs  was  responsible  for  immunosuppression.  Additional  experiments   using  PαS  MSCs  isolated  from  transgenic  iNOS-­‐/-­‐  mice  provided  further  proof  for  this  finding.   A   comparative   study   by   Ren   et   al.   (2009)   identified   that   mouse   MSCs   exclusively   use   NO   secretion   to   immunosuppress   while   human   MSCs   secrete   IDO.   Our   findings   back   up   this   hypothesis,  as  we  did  not  see  any  effect  when  using  an  IDO  inhibitor.  It  is  interesting  to  note   that   inhibition   of   NO   secretion   caused   a   complete   reversal   in   the   immunosuppressive   phenotype  of  PαS  MSCs.  Past  studies  have  noted  that  neutralisation  of  one  factor  secreted   by  mouse  or  human  MSCs  does  not  result  in  a  complete  reversal  of  suppression,  suggesting   that  there  are  other  factors  in  play  (Ben-­‐Ami  et  al.,  2011).  This  degree  of  redundancy  could   be  due  to  the  heterogeneous  stromal  populations  used  in  past  studies,  with  each  having  a  

different  mechanism  of  immunosuppression.  The  purified  population  of  PαS  MSCs  used  in   this  study  displayed  a  ‘unified’  response  to  the  compounds  tested  and  demonstrates  nicely   how  prospective  isolation  could  help  reduce  diversity  in  the  MSC  field.    

   

NO  is  a  potent  signalling  molecule  with  a  short  half-­‐life  that  is  involved  in  many  physiological   processes  ranging  from  vasodilation  to  immune  regulation  (Bogdan,  2001).  NO  production   by  macrophages  has  been  shown  to  suppress  T  cell  proliferation  via  the  inhibition  of  STAT5   phosphorylation,  resulting  in  cell  cycle  arrest   (Mazzoni  et  al.,  2002,  Bingisser  et  al.,  1998).   Interestingly,  Sato  et  al.  (2007)  identified  the  same  mechanism  at  play  with  murine  MSCs,   highlighting   the   importance   of   the   NO-­‐STAT5   axis.   Future   work   could   include   western   blotting  for  phosphorylated  STAT5  in  CD4  T  cells  to  identify  whether  the  same  mechanism   occurs  with  PαS  MSC  co-­‐culture.    

 

Recent   studies   have   identified   MSCs   as   key   players   in   the   HSC   niche,   as   they   are   the   precursors   of   multiple   niche   components   and   can   secrete   factors   that   are   crucial   for   HSC   maintenance   (Frenette   et   al.,   2013).   However,   the   physiological   role   for   MSC-­‐mediated   immunosuppression   and   NO   release   in   the   BM   niche   is   unclear.   Some   authors   have   suggested   that   MSCs   may   function   to   protect   HSCs   from   immune   mediated   damage   by   creating  an  ‘immunoprivileged  zone’  around  these  cells  (Hsu  and  Fuchs,  2012).  However,  an   elegant  imaging  study  by  Fujisaki  et  al.  (2011)  demonstrates  that  Tregs  co-­‐localise  with  HSCs  

in  vivo  to  create  an  immunoprivileged  site  that  enabled  allogeneic-­‐HSCs  to  avoid  rejection  

remains  to  be  seen  whether  they  do  play  an  immunosuppressive  role  in  the  BM  niche.  Data   from  the  Matsuzaki  group  suggest  that  mismatched  naïve  PαS  MSCs  can  trigger  the  onset  of   GvHD  in  a  mouse  model  of  BM  transplantation  (Ogawa  et  al.,  2012).  The  selective  depletion   of  PαS  MSCs  from  BM  grafts  reduced  fibrosis  across  all  organs.  From  these  findings,  it  can  be   speculated  that  naïve  PαS  MSCs  directly  isolated  from  their  niche  are  not  suppressive  and   that  immunosuppression  is  a  property  acquired  through  in  vitro  culture.  This  hypothesis  is   further  backed  up  by  the  various  human  phase  I/II  trials  using  in  vitro  cultured  MSCs  in  the   treatment  of  GvHD  that  report  favourable  outcomes  (Le  Blanc  et  al.,  2008,  Le  Blanc  et  al.,   2004b).  Future  studies  using  freshly-­‐isolated  PαS  cells  in  immunosuppression  assays  would   be  required  to  test  this  hypothesis.    

 

  3.2.4  Strain-­‐specific  differences  in  Immunosuppression  

PαS  MSCs  isolated  from  C57BL/6  mice  failed  to  suppress  T  cell  proliferation  in  our  standard   assay,   leading   us   to   hypothesise   that   there   might   be   strain-­‐specific   differences   in   the   immunosuppressive  mechanism  of  MSCs  isolated  from  Balb/c  and  C57BL/6  mice.  Hashemi  et   al.  (2013)  compared  the  immunosuppressive  properties  of  conditioned  media  (CM)  isolated   from  adipose-­‐derived  MSCs  of  Balb/c  and  C57BL/6  mice.  They  report  that  Balb/c  MSC  CM  is   more  suppressive  than  C57BL/6-­‐derived  CM,  partly  due  to  higher  levels  of  IDO,  TGF-­‐β  and   NO  in  Balb/C  MSC  supernatants.  Although  a  comparative  study  of  immunosuppression  from   BM-­‐derived   MSCs   has   not   yet   been   performed,   one   can   assume   with   the   differences   observed  in  CFU-­‐F  and  differentiation  from  different  mouse  strains  that  immunosuppression   may  vary  as  well.      

We  hypothesised  that  C57BL/6-­‐derived  PαS  MSCs  were  exerting  an  indirect  effect  on  T  cell   proliferation   by   inhibiting   antigen   presentation   or   polarising   macrophages   towards   a   regulatory   phenotype.   To   test   this   hypothesis,   we   moved   away   from   a   ‘purified’   system   where   no   antigen   presentation   was   required   to   a   more   complex   splenocyte   culture   containing  several  different  immune  cell  subsets.  After  unsuccessful  attempts  to  stimulate   splenocyte  cultures  with  ConA  or  Dynabeads®,  the  OT-­‐1  transgenic  mouse  was  chosen  as  our   model   system.   CD8   T   cells   from   OT-­‐1   mice   have   a   TCR   specific   for   the   ovalbumin   protein   (Wright   et   al.,   2005).   Exogenous   addition   of   OVA   peptide   into   OT-­‐1   splenocyte   cultures   causes  antigen-­‐specific  proliferation  of  CD8  lymphocytes  (Clarke  et  al.,  2000).  OVA  peptide   needs  to  be  processed  and  presented  in  a  MHC  class  I  context  to  CD8  lymphocytes  to  cause   activation,   thereby   making   this   system   more   physiologically   relevant   than   the   use   of   TCR-­‐ binding  antibodies  or  beads.  It  is  also  a  good  in  vitro  representation  of  the  OVA-­‐Bil  mouse   model,  where  ectopic  expression  of  OVA  on  the  biliary  epithelium  of  the  liver  results  in  an   OT-­‐1  mediated  immune  reaction  and  inflammation  (Buxbaum  et  al.,  2006).    

 

Our  preliminary  findings  show  that  C57BL/6-­‐derived  PαS  MSCs  can  suppress  CD8  lymphocyte   proliferation  in  a  dose-­‐dependent  manner.  We  also  saw  reductions  in  the  IFNγ  production  of   CD8   cells   after   MSC   co-­‐culture,   a   finding   that   has   been   shown   before   by   Hof-­‐Nahor   and   colleagues  for  human  MSCs  (Hof-­‐Nahor  et  al.,  2012).  Interestingly,  although  there  were  large   drops   in   total   numbers   of   CD8   T   cells   after   PαS   MSC   co-­‐culture,   we   only   observed   minor   differences  in  the  proliferation  status  of  CD8  cells  that  remained  viable.  This  suggests  that   MSCs   could   induce   CD8   lymphocyte   apoptosis   and   that   any   lymphocytes   which   escaped  

MSC-­‐mediated  immunosuppression  were  still  proliferating  in  response  to  OVA  antigen.  The   induction  of  CD8  T  cell  apoptosis  has  been  reported  previously  for  human  MSC  populations   due  to  IDO-­‐mediated  depletion  of  tryptophan  from  the  local  microenvironment  (Plumas  et   al.,  2005).  Further  experiments  are  needed  to  see  whether  a  similar  mechanism  is  in  play  for   PαS  MSCs.  Further  repeats  are  also  needed  to  increase  the  sample  size  and  to  understand   the   significance   of   these   findings.   Small   molecule   inhibitors   of   known   immunosuppressive   pathways  can  be  added  to  the  splenocyte  reaction  to  try  and  identify  a  mechanism  of  action.   Additionally,  individual  immune  cell  subsets  (e.g.  monocytes/macrophages,  B  cells,  DCs)  can   be   selectively   removed   from   the   splenocyte   mixture   to   study   indirect   effects   on   T   cell   proliferation.      

                       

CHAPTER  4